The Oncology Institute, Inc.
NASDAQ:TOIMedical - Care Facilities
-$0.07 today
- Market cap
- $512.91M
- Beta
- 0.41
- P/E (TTM)
- -121.1
- EPS (TTM)
- -$0.04
Volume 1.21M
Average 1.74M
TOI EBITDA Margin
EBITDA as a percentage of revenue.
The Oncology Institute, Inc.NASDAQ: TOI
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to 0.7%
EBITDA Margin was 0.7% in Q1 FY2026, up 12.4 pp from a year earlier. On a trailing-twelve-month basis it was -5.4%, up 6.2 pp year over year. Over 3 fiscal years it widened by 18.3 pp.
Context
- EBITDA Margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 3 analysts of -17.1% for the fiscal year ending Dec 2026, down from -8.5% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 0.7%+3.5 pp QoQ
- Last fiscal yearDec 2025
- -8.5%+4.5 pp YoY
- LTMMar 2026
- -5.4%+6.2 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +12.4 pp | -5.9 pp | -18.3 pp |
| 1 year | +4.5 pp | -8.7 pp | -13.1 pp |
| 3 years | +18.3 pp | -8.7 pp | -27.0 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -8.5%
- Year-over-year change
- +4.5pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -8.5% | +4.5pp |
| FY2024 | 2024-12-31 | -12.9% | +3.8pp |
| FY2023 | 2023-12-31 | -16.7% | +10.0pp |
| FY2022 | 2022-12-31 | -26.8% | -6.1pp |
| FY2021 | 2021-12-31 | -20.7% | — |
EBITDA Margin vs competitors
How TOI compares with its peers on the latest reported figures
- TOI's LTM Mar 2026 EBITDA Margin of -5.4% is the 5th highest of the 10 companies compared; the peer median is -5.9%.
- Its year-over-year change of +6.2 pp is the 3rd highest of 10, against a peer median of -2.1 pp.
- Over three fiscal years its change of +18.3 pp compares with a peer median of +5.3 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
AUNAAuna S.A. | LTM Mar 2026 | 17.5% | -1.2 pp | +7.3 pp |
| LTM Mar 2026 | 1.2% | -11.7 pp | -1.1 pp | |
| LTM Mar 2026 | -2.7% | +3.5 pp | +2.1 pp | |
| LTM Mar 2026 | -4.6% | +6.2 pp | +28.7 pp | |
| LTM Mar 2026 | -5.4% | +6.2 pp | +18.3 pp | |
| LTM Mar 2026 | -5.9% | -2.2 pp | -3.2 pp | |
| LTM Mar 2026 | -6.8% | -7.5 pp | -16.1 pp | |
| LTM Mar 2026 | -22.3% | -4.0 pp | +5.3 pp | |
CBLLCeriBell, Inc. | LTM Mar 2026 | -60.2% | -2.1 pp | +78.9 pp |
| LTM Mar 2026 | -249.3% | +2401.7 pp | +1803.8 pp | |
| Peer median (excluding TOI) | -5.9% | -2.1 pp | +5.3 pp | |
Competitors are the stored peer set for TOI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 203M | 252.48M | 324.24M | 393.41M | 502.73M |
| Cost of Revenue | 162.16M | 200.39M | 264.67M | 339.42M | 426.29M |
| Gross Profit | 40.85M | 52.09M | 59.57M | 54M | 76.44M |
| Gross Margin | 20.1% | 20.6% | 18.4% | 13.7% | 15.2% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 0 | 0 | 0 | 0 | 105.57M |
| Operating Expenses | 86.71M | 134.04M | 136.59M | 114.12M | 112.52M |
| Depreciation & Amortization | 3.34M | 4.41M | 5.87M | 6.29M | 6.94M |
| EBITDA | (42.04M) | (67.6M) | (54.28M) | (50.88M) | (42.52M) |
| EBITDA Margin | -20.7% | -26.8% | -16.7% | -12.9% | -8.5% |
| Operating Income | (45.86M) | (81.95M) | (77.02M) | (60.12M) | (36.08M) |
| Operating Margin | -22.6% | -32.5% | -23.8% | -15.3% | -7.2% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 320K | 4.08M | 6.78M | 7.5M | 11.28M |
| Other Income / Expenses | 34.26M | 81.86M | (6.09M) | (4.55M) | (24.65M) |
| Income Before Tax | (11.6M) | (91K) | (83.1M) | (64.66M) | (60.74M) |
| Pre-Tax Margin | -5.7% | -0.0% | -25.6% | -16.4% | -12.1% |
| Income Tax Expense | (671K) | (243K) | (36K) | 0 | (131K) |
| Net Income | (10.93M) | 152K | (83.07M) | (64.66M) | (60.61M) |
| Net Margin | -5.4% | 0.1% | -25.6% | -16.4% | -12.1% |
| EPS (Basic) | (0.16) | 0.00 | (0.92) | (0.71) | (0.54) |
| EPS (Diluted) | (0.16) | (0.21) | (0.92) | (0.71) | (0.54) |
| Weighted Avg Shares | 66.23M | 72.79M | 73.75M | 75.04M | 923.89M |
| Weighted Avg Shares (Diluted) | 66.23M | 80.61M | 73.75M | 75.04M | 923.89M |
The Oncology Institute, Inc.
NASDAQ:TOI
Intrinsic Alpha fair value
Locked
Current Price
$5.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.